The present invention relates to a stable solid oral dosage form of linaclotide that exhibits delayed release of linaclotide into the lower gastrointestinal tract. In addition, the present invention provides methods for treating medical conditions by administering these delayed release compositions. The delayed release compositions of the present invention may be used to treat a variety of medical conditions, such as irritable bowel syndrome (“IBS”) (eg, IBS “IBS-c” with constipation, IBS with diarrhea “IBS” -D ", or mixed IBS with constipation and diarrhea (IBS-m)), constipation (eg, chronic idiopathic constipation), colon cancer, diverticulitis, interstitial cystitis, and gastrointestinal tracts such as abdominal or visceral pain Particularly suitable for the treatment of disorders.本発明は、下部胃腸管へのリナクロチドの遅延放出を呈するリナクロチドの安定した固形経口剤形に関する。加えて、本発明は、これらの遅延放出組成物を投与することによって病状を治療する方法を提供する。本発明の遅延放出組成物は、種々の病状を治療するために使用され得るが、過敏性腸症候群（「ＩＢＳ」）（例えば、便秘を伴うＩＢＳ「ＩＢＳ－ｃ」、下痢を伴うＩＢＳ「ＩＢＳ－ｄ」、又は便秘及び下痢を伴う混合型ＩＢＳ「ＩＢＳ－ｍ」）、便秘（例えば、慢性突発性便秘）、結腸癌、憩室炎、間質性膀胱炎、並びに腹部又は内臓痛等の胃腸障害の治療に特に適している。
